Cart (0 Items)
Your cart is currently empty.
View Products
We are proud to partner with 9 000+ customers from biotech innovators, pharmaceutical leaders, and academic pioneers worldwide.
Inspired by your projects, together we are shaping the therapeutic innovations of tomorrow. Explore here the achievements of our team – shared successes that showcase the impact of our partnership.
CASE REPORT
-
Accelerating NANOBODY® VHH Discovery for Translational Development
ProteoGenix helped Heidelberg University rapidly progress from antigen to validated NANOBODY® leads through phage display expertise, rigorous screening, and dedicated scientific support.
-
From AI Prediction to Experimental Proof – 85% Signal Reduction with AIxplore® Epitope & Paratope Mapping
By combining AI predictions with experimental validation, ProteoGenix delivered reliable antibody–antigen insights, reducing risks and timelines and guiding therapeutic, diagnostic, and IP strategies.
-
TCR-Like Antibody Development For Cancer Immunotherapy
ProteoGenix rapidly generated high-affinity TCR-like antibodies against a difficult peptide–HLA target, using rabbit immunization and a custom phage display library. This approach delivered three validated candidates that advanced the client’s CAR-T immunotherapy program.
SUCCESS STORIES
-
How a Unique Monoclonal Antibody Development Approach Helped Recce Pharmaceuticals Overcome Regulatory Hurdles
ProteoGenix engineered highly specific antibodies for Recce’s RECCE® 327, enabling reliable pharmacokinetic assays and supporting the drug’s progress through key regulators.
-
TELUM Therapeutics Partners with ProteoGenix for Custom Monoclonal Antibody Services in EpIeTTX1 Pharmacokinetic Monitoring
ProteoGenix delivered highly specific antibodies to detect intact EpIeTTX1, giving TELUM the precise pharmacokinetic data needed to advance their antimicrobial therapy.
-
The Path of Creating an Innovative IL-17A Antibody for Autoimmune Disorders
ProteoGenix created a potent neutralizing IL-17A antibody that enabled the Naples and Birmingham teams to block IL-17A-driven inflammation and advance a patented therapeutic strategy for autoimmune diseases.
-
Next-Generation Antibody Discovery Enabled By NativeMP™ and Phage Display Technology
ProteoGenix and Cube Biotech created two fully human, high-specificity antibodies against native P2X4, unlocking new opportunities for drug discovery in cardiovascular and inflammatory diseases.
-
Antibody Phage Display for Diagnostic Application
Accelerating Translational Research: How Phage Display Technology Delivered High-Affinity Antibodies for Groundbreaking Applications
ProteoGenix leveraged phage display to deliver high-affinity antibodies against a difficult cell surface target, helping UCL advance their research toward preclinical development.
-
Antibody Library Generation for Phage Display
Pioneering the Development of Therapeutic Antibodies for Alzheimer’s Disease
ProteoGenix used its LiAb-SFMAX™ phage display platform to generate a fully human antibody targeting TREM-2, enabling Isar Bioscience to advance a patented therapeutic candidate for Alzheimer’s disease.
-
Hybridoma development services
A cross-reactive antibody unravels the unexpected trigger of an aggressive autoimmune disease
ProteoGenix generated a cross-reactive antibody that helped uncover how shared epitopes between PLA2R and THSD7A may trigger membranous nephropathy, enabling researchers to clarify disease mechanisms and advance early diagnostic strategies.
-
Hybridoma development services
Hybridoma-based antibody development: Targeting Key Protein in Long QT Syndrome and Advancing Cardiac Research
Discover how antibody optimization is key for the translation development of complex molecules such as NANOBODY® Proteins
-
Ascites and Hybridoma cell culture antibody production
Can antibodies help us identify elusive single-point mutations and quickly determine the prognosis in complex disease landscapes?
ProteoGenix developed variant-specific antibodies that detect a single-point mutation in IGLV3-21, helping researchers identify high-risk CLL patients and improve early prognosis assessment.
Let’s get in touch
Need a personalized consultation or a quote ? Message us and we will get back to you in less than 48 hours.